

MicroPort Released New Products to its Nationwide Distributors

April 28, 2014 – Shanghai MicroPort Medical (Group) Co., Ltd. released 19 new products to its nationwide distributors. The event has attracted more than 260 participants nationwide.

2013 Annual Report Released

MicroPort Scientific Corporation released the 2013 annual report on the company's website (www.microport.com) and the Stock Exchange of Hong Kong Limited (www.hkexnews.hk), on April 30, 2013.

Firehawk® Stent Debut in Guangzhou Lingnan Conference

Shanghai MicroPort Medical (Group) Co., Ltd. participated Guangzhou Lingnan Conference which held from April 10 to 13 and the official appearance of Firehawk® Rapamycine Target Eluting Coronary Stent System received great attention.

Contents

MicroPort Released New Products to its Nationwide Distributors

2013 Annual Report Released

Firehawk® Stent Debut in Guangzhou Lingnan Conference

MicroPort Released New Products to its Nationwide Distributors



Shanghai – April 28, 2014 – Shanghai MicroPort Medical (Group) Co ("MicroPort") released 35 new products, mostly designed and manufactured by MicroPort and its subsidiaries, to its nationwide distributors. These new products, cover a wide range of business segments including cardiovascular, orthopedic, electrophysiological, endovascular, neurovascular, surgical, cardiac rhythm management devices, and have attracted more than 260 participants nationwide, seeking opportunities to act as product distributors.

The event features several star products that are about to shake current markets and lead future development in their respective segments. One is Firehawk Rapamycin Target Eluting Coronary Stent, the world's first and only Target Eluting Stent ("TES") that enables the device to achieve the same clinic efficacy as the traditional drug-eluting stent ("DES") with the least drug

dosage. Compared to DES, its unique design lowers around 68 percent of drug use, greatly improving safety for patients. The product gained approval for market launch in China in late January and MicroPort is now applying for CE mark to bring this innovation to the European market.

Willis Intracranial Stent, another revolutionary device, is the first of its kind in China designed to treat intracranial aneurysms, and is expected to continue dominating the market in the next five years. MicroPort intends to launch Willis into the international markets in 2015.


"MicroPort is expanding toward a diversified global conglomeration from a new start," said Bo Peng, Chairman of Greater China Executive Committee and Chief Marketing Officer, referring to the company's recent developments, such as its large outbound acquisitions of Wright OrthoRecon business in 2013, and the latest move to establish a joint venture with Italy-based Sorin Group for CRM business. "At this point, we are looking forward to seeing more distributors join us and to build an even more successful future together."

"We have built wealth by selling MicroPort's products as a distributor in the past 10 years," said Xianghong Fang, General Manager of Beijing Kerui Huakang Medical Company. "We are expecting the next 10 years working with MicroPort to bring great success, with so many promising products newly released."

Back to Top

Disclaimer: The content below is for communication purpose only. Our company and its affiliates do not guarantee to anybody that the information below is complete and up-to-date. Our company and its affiliates do not accept any responsibility for any decision made as a result of relying on the information contained herein.

2013 Annual Report Released



MicroPort Scientific Corporation released the 2013 annual report on the company's website (www.microport.com) and the Stock Exchange of Hong Kong Limited (www.hkexnews.hk), on April 30, 2013.

The profit and revenue of MicroPort for the fiscal year 2013 was RMB 149 million and RMB 939 million respectively.

Back to Top

Firehawk® Stent Debut in Guangzhou Lingnan Conference



Shanghai MicroPort Medical (Group) Co., Ltd. participated Guangzhou Lingnan Conference which was held from April 10 to 13. The official appearance of Firehawk® Rapamycine Target Eluting Coronary Stent System received great attention.

On April 11, the conference featured an international forum and live case demonstration on coronary interventional operations. Mr. Bo Xu, professor from the Chinese National Center for Cardiovascular Disease Fuwai Hospital, expressed his great confidence in Firehawk Stent's innovative TES (Target Eluting Stent) drug delivery system and recognized the safety and effectiveness of the stent.

Back to Top